Samsung Electronics has entered into a strategic partnership with clinical research organisation Alcedis to strengthen the use of wearable technology in medical research. The collaboration aims to convert biometric data collected through Samsung’s wearable devices into clinically meaningful evidence, helping improve the speed and quality of clinical trials and drug development.

Samsung Electronics has announced a new partnership with Alcedis, a digital-first clinical research organisation (CRO), to advance the use of wearable technology in clinical studies. The collaboration focuses on transforming physiological data collected through Samsung wearables into reliable clinical evidence that can support pharmaceutical research and healthcare innovation.

As wearable devices become increasingly capable of capturing continuous, real-world health information, researchers have gained access to more patient data than ever before. However, translating that information into validated clinical endpoints has remained a significant challenge. Samsung and Alcedis aim to address this gap by combining their respective strengths in digital health technology and clinical trial management.

Samsung will contribute its wearable technology ecosystem, including Galaxy Watch biosensors, clinically validated health measurements such as bioelectrical impedance analysis (BIA) and electrodermal activity (EDA), along with Software as a Medical Device (SaMD) capabilities like obstructive sleep apnea (OSA) and atrial fibrillation (AFib) detection. These technologies will be supported by Samsung’s biomarker research expertise and technical infrastructure developed for clinical evidence generation.

Alcedis, which specialises in data-driven clinical trials, will oversee study execution, participant engagement and clinical research operations. Together, the companies intend to develop digital biomarkers and wearable-based endpoints that can be incorporated into future clinical studies, potentially reducing both research timelines and operational costs.

The collaboration is expected to support faster study setup by providing researchers with greater control over wearable biosensors and improved access to participant-level health insights collected in real-world settings. This approach is designed to help bridge the gap between everyday health monitoring and regulated clinical research, creating new opportunities for evidence-based drug development.

The partnership also reflects the growing role of connected health technologies in clinical research, where continuous patient monitoring is becoming increasingly valuable for understanding disease progression, evaluating treatments and developing patient-centric healthcare solutions. By integrating wearable-generated data with structured clinical research workflows, Samsung and Alcedis aim to strengthen the use of digital health technologies throughout the research lifecycle.

Source: This article is based on an official press release issued by Samsung Electronics
Samsung Partners With Alcedis To Advance Clinical Research Using Wearable-Based Endpoints – Samsung Newsroom India